Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess the Incidence of Mutations in the Tyrosine Kinase Domain of the Endothelial Growth Factor Receptor in UK Patients With Newly Diagnosed Metastatic or Recurrent Non-small Cell Lung Cancer and to Investigate the Quality of Life of These Patients Undergoing First-line Therapy With Erlotinib.

NCT01250119 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01250119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01250119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess the Incidence of Mutations in the Tyrosine Kinase Domain of the Endothelial Growth Factor Receptor in UK Patients With Newly Diagnosed Metastatic or Recurrent Non-small Cell Lung Cancer and to Investigate the Quality of Life of These Patients Undergoing First-line Therapy With Erlotinib.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
May 31, 2014
Enrollment
688 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer